$CVS · CVS HEALTH Corp
CVS Health's 10-Q for Q3 FY2026 shows total revenue of $108.399B, up 5.4% year over year, with net income attributable to CVS of $2.172B versus a $3.975B loss in Q3 2025. The prior-year loss was driven by a $5.725B goodwill impairment that did not recur. Nine-month net income reached $8.094B versus a $1.175B loss a year earlier, and operating cash flow nearly doubled to $15.318B from $7.249B.
- Q3 revenue rose 5.4% to $108.399B, led by products up 7.2% to $69.225B.
- Q3 diluted EPS was $1.68 versus a $3.13 loss per share a year ago.
- Nine-month operating cash flow jumped to $15.318B from $7.249B.
- The $5.725B goodwill impairment from Q3 2025 did not recur in 2026.
- Nine-month net income attributable to CVS was $8.094B versus a $1.175B loss.
Markets closed — no regular-session reaction yet; extended-hours last trade at $91.56, up 0.16% from the $91.41 close.
CVS's return to profitability is largely a base-effect story from a non-recurring goodwill impairment, but the near-doubling of operating cash flow signals genuine operational improvement.
The swing to profit reflects a clean comparison against a goodwill-impairment-distorted 2025, a pattern common across diversified healthcare payers and pharmacy chains.
The filing notes a planned separation of a business segment that remains contingent on SEC clearance and confirmation the transaction is tax-free to CVS and shareholders.